Pilot study pits cologuard against FIT for colon cancer screening in younger adults
NCT ID NCT06173375
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study compared two stool-based tests—Cologuard and the fecal immunochemical test (FIT)—for colorectal cancer screening in adults aged 45-49. Researchers mailed the tests to eligible participants and tracked how many completed screening, had abnormal results, and followed up with a colonoscopy. The study involved only 12 people and aimed to see which test works better for this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cologuard (multi-target stool DNA test) and Fecal Immunochemical Test (FIT)
- What this could lead to
- If successful, this could help determine which stool-based screening method is more effective for colorectal cancer detection in younger adults.
- What could go wrong
- This is a very small pilot study with only 12 participants, so results may not apply to larger populations. It does not test new treatments or cures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Diego
La Jolla, California, 92126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?